摘要
目的探讨慢性阻塞性肺疾病(chronic obstructive pulmoriary disease,COPD)患者采用沙美特罗氟替卡松联合噻托溴铵治疗的临床疗效。方法选取赤峰松山医院2020年1月-2021年12月收治的104例慢性阻塞性肺疾病患者,以数字单双数抽签方式将其分为两组,每组52例。对照组采用沙美特罗氟替卡松进行治疗,研究组采用沙美特罗氟替卡松联合噻托溴铵治疗。比较两组患者的临床疗效。结果研究组治疗后用力肺活量(FVC)为(2.13±0.42)L,低于对照组的(2.58±0.32)L,差异有统计学意义(t=6.146,P<0.05)。研究组第1秒用力呼气容积(FEV1)及第1秒用力呼气容积/用力肺活量(FEV1/FVC)分别为(2.23±0.51)L和(63.45±1.79)%,均高于对照组(1.56±0.46)L和(53.06±1.78)%,差异有统计学意义(t=7.035、29.680,P<0.05)。研究组患者不良反应发生率(1.92%)明显低于对照组(15.38%),研究组患者治疗后的1年内急性发作次数少于对照组,差异有统计学意义(P<0.05)。结论沙美特罗氟替卡松联合噻托溴铵可有效减轻慢阻肺患者的临床病症,有助于提升肺功能水平,同时,在不良反应的发生率上有更好的控制效果,具有临床推广价值。
Objective To investigate the clinical efficacy of the treatment of patients with chronic obstructive pulmo⁃nary disease(COPD)with salmeterol fluticasone combined with tiotropium bromide.Methods A total of 104 patients with chronic obstructive pulmonary disease who were admitted to Chifeng Songshan Hospital from January 2020 to December 2021 were selected.They were divided into two groups for comparative investigation by means of digital odd and even numbers,with 52 cases in each group.The control group was treated with salmeterol-fluticasone,and the study group was treated with salmeterol-fluticasone combined with tiotropium bromide.The clinical efficacy of the two groups of patients was compared.Results After treatment,the forced vital capacity(FVC)of the study group was(2.13±0.42)L,which was lower than that of the control group(2.58±0.32)L,the difference was statistically sig⁃nificant(t=6.146,P<0.05).The forced expiratory volume in one second(FEV1),forced expiratory volume in one sec⁃ond/forced vital capacity(FEV1/FVC)of the study group were(2.23±0.51)L and(63.45±1.79)%,higher than those of the control group(1.56±0.46)L and(53.06±1.78)%,respectively,the difference was statistically significant(t=7.035,29.680,P<0.05).The incidence of adverse reactions in the study group(1.92%)was significantly lower than that in the control group(15.38%),the number of acute attacks in the study group was less than that in the control group within one year after treatment,and the difference was statistically significant(P<0.05).Conclusion Salmeterol fluti⁃casone combined with tiotropium bromide can effectively relieve the clinical symptoms of patients with COPD,help to improve the level of lung function,and at the same time,it has a better control effect on the incidence of adverse reactions,which has clinical promotion value.
作者
穆喜泉
MU Xiquan(Department of Respiratory and Critical Care Medicine,Songshan Hospital,Chifeng,Inner Mongolia Autonomous Re-gion,024000 China)
出处
《系统医学》
2022年第11期60-63,共4页
Systems Medicine
关键词
沙美特罗氟替卡松
噻托溴铵
慢阻肺
肺功能指标
SGQR评估
Salmeterol fluticasone
Tiotropium bromide
Chronic obstructive pulmonary disease
Pulmonary function index
SGQR assessment
